On the Role of Corticotropin-releasing Hormone Receptors in Anxiety and Depression

Overview

Journal Dialogues Clin Neurosci

Specialty Neurology

Date 2011 Oct 29

PMID 22033745

Citations 45

Authors

Johannes M H M Reul

Florian Holsboer

Affiliations

Soon will be listed here.

Abstract

On the basis of extensive basic and clinical studies, corticotropin-releasing hormone (CRH) and its related family members are considered to play a pivotal role in stress-related disorders, such as anxiety and depression. CRH is regarded as the principal mediator in the brain of the stress response, as it mediates neuroendocrine, autonomic, and behavioral responses to stressful challenges. Recently, this neuropeptide family has expanded due to the discovery of two new members, urocortin II (also termed stresscopin-related peptide) and urocortin III (also termed stresscopin), which are selective agonists for the CRH receptor type 2. They show a discrete neuroanatomical localization and are involved in stress-coping responses, such as anxiolysis. Here, on the basis of recent developments, we suggest that CRH, the urocortins, and their receptors form a complex system in the brain, which is recruited during both the acute and the recovery phases of the stress response.

Citing Articles

Glucocorticoid Resistance Syndrome in 2 Patients With Diverse Genotype.

Battiola T, Viskochil D, Wolken K, Couldwell M JCEM Case Rep. 2025; 3(2):luae243.

PMID: 39850725 PMC: 11756296. DOI: 10.1210/jcemcr/luae243.

Comparative Efficacy of Animal Depression Models and Antidepressant Treatment: A Systematic Review and Meta-Analysis.

Ratajczak P, Martynski J, Zieba J, Swilo K, Kopciuch D, Paczkowska A Pharmaceutics. 2024; 16(9).

PMID: 39339181 PMC: 11435171. DOI: 10.3390/pharmaceutics16091144.

Molecular basis of urostyle development in frogs: genes and gene regulation underlying an evolutionary novelty.

Senevirathne G, Shubin N Open Biol. 2024; 14(8):240111.

PMID: 39191278 PMC: 11349433. DOI: 10.1098/rsob.240111.

Depression and the Glutamate/GABA-Glutamine Cycle.

Mamelak M Curr Neuropharmacol. 2024; 23(1):75-84.

PMID: 39150032 PMC: 11519819. DOI: 10.2174/1570159X22666240815120244.

Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models.

Yang Y, Chen Y, Xie M World J Psychiatry. 2024; 14(5):607-623.

PMID: 38808079 PMC: 11129158. DOI: 10.5498/wjp.v14.i5.607.

References

Keck M, Holsboer F . Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides. 2001; 22(5):835-44. DOI: 10.1016/s0196-9781(01)00398-9. View

Holsboer F . The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000; 23(5):477-501. DOI: 10.1016/S0893-133X(00)00159-7. View

Bale T, Contarino A, Smith G, Chan R, GOLD L, Sawchenko P . Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet. 2000; 24(4):410-4. DOI: 10.1038/74263. View

Lovenberg T, Liaw C, Grigoriadis D, Clevenger W, Chalmers D, DE SOUZA E . Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A. 1995; 92(3):836-40. PMC: 42715. DOI: 10.1073/pnas.92.3.836. View

Lewis K, Li C, PERRIN M, Blount A, Kunitake K, Donaldson C . Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A. 2001; 98(13):7570-5. PMC: 34709. DOI: 10.1073/pnas.121165198. View

Seasholtz A, Burrows H, Karolyi I, Camper S . Mouse models of altered CRH-binding protein expression. Peptides. 2001; 22(5):743-51. DOI: 10.1016/s0196-9781(01)00387-4. View

Smith G, Aubry J, Dellu F, Contarino A, Bilezikjian L, GOLD L . Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 1998; 20(6):1093-102. DOI: 10.1016/s0896-6273(00)80491-2. View

Martinez V, Tache Y . Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res. 2001; 893(1-2):29-35. DOI: 10.1016/s0006-8993(00)03277-7. View

Holsboer F, von Bardeleben U, Wiedemann K, Muller O, Stalla G . Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry. 1987; 22(2):228-34. DOI: 10.1016/0006-3223(87)90237-x. View

10.

Holsboer F, von Bardeleben U, Steiger A . Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology. 1988; 48(1):32-8. DOI: 10.1159/000124986. View

11.

Holsboer F . The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999; 33(3):181-214. DOI: 10.1016/s0022-3956(98)90056-5. View

12.

Heinrichs S, de Souza E, Schulteis G, Lapsansky J, Grigoriadis D . Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 2002; 27(2):194-202. DOI: 10.1016/S0893-133X(02)00299-3. View

13.

Crawley J . Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 1999; 835(1):18-26. DOI: 10.1016/s0006-8993(98)01258-x. View

14.

Opp M . Corticotropin-releasing hormone involvement in stressor-induced alterations in sleep and in the regulation of waking. Adv Neuroimmunol. 1995; 5(2):127-43. DOI: 10.1016/0960-5428(95)00004-l. View

15.

Keck M, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F . The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci. 2001; 13(2):373-80. DOI: 10.1046/j.0953-816x.2000.01383.x. View

16.

Nemeroff C, Owens M, Bissette G, Andorn A, Stanley M . Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 1988; 45(6):577-9. DOI: 10.1001/archpsyc.1988.01800300075009. View

17.

de Kloet E, Vreugdenhil E, Oitzl M, Joels M . Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998; 19(3):269-301. DOI: 10.1210/edrv.19.3.0331. View

18.

Swanson L, Sawchenko P . Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu Rev Neurosci. 1983; 6:269-324. DOI: 10.1146/annurev.ne.06.030183.001413. View

19.

Brunner B, Grutzner F, Yaspo M, Ropers H, Haaf T, Kalscheuer V . Molecular cloning and characterization of the Fugu rubripes MEST/COPG2 imprinting cluster and chromosomal localization in Fugu and Tetraodon nigroviridis. Chromosome Res. 2000; 8(6):465-76. DOI: 10.1023/a:1009263504671. View

20.

Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F . Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res. 1999; 33(2):153-63. DOI: 10.1016/s0022-3956(98)80047-2. View